Publication
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerAcral Lentiginous Melanomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- drugBinimetinibcivic_curation1.00
- geneRAF1civic_curation1.00
- variantRAF1 Fusioncivic_curation1.00
- variantRAF1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 39504576
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RAF1 Fusion1 | ||||||||
| Binimetinib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13148An 88-year-old patient with metastatic acral melanoma harboring a GOLGA4-RAF1 fusion received binimetinib 45 mg twice daily after progression on multiple immunotherapy regimens and clinical deteriorat… (full text at CIViC) PMID 39504576 · Khaddour et al., 2025 · Open in CIViC | civic |
| RAF1 Fusion1 | ||||||||
| Binimetinib | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13147A patient with metastatic melanoma harboring a GCC2-RAF1 fusion involving RAF1 intron 7 (which retains the kinase domain) received binimetinib 45 mg twice daily after progression on multiple prior sys… (full text at CIViC) PMID 39504576 · Khaddour et al., 2025 · Open in CIViC | civic |